Cumulus Neuroscience to Present at AAIC 2024 Annual Meeting and Technology & Dementia Preconference

Cumulus Neuroscience, a global digital health company, will reveal significant findings from its CNS-101 study at the Alzheimer's Association International Conference (AAIC) 2024 in Philadelphia, Pennsylvania. The study, undertaken in collaboration with the University of Cambridge, focuses on evaluating functional neurophysiology in patients with mild Alzheimer’s dementia in a home setting.

Two key posters have been accepted by the AAIC Scientific Program Committee for presentation at both the Technology and Dementia Preconference and the main AAIC meeting. Additionally, one of the posters will also be presented during the Technology and Dementia Preconference Data Blitz. The poster details are as follows:

1. Technology and Dementia Preconference
- Title: Machine-learning analysis of real-world multimodal data collected autonomously at home detects dementia as precisely as a traditional composite scale
- Session: Technology and Dementia Preconference Posters
- Date & Time: Saturday, July 27, 2024, 8:00 AM – 3:00 PM EDT
- Poster Number: 94323

2. Technology and Dementia Preconference
- Title: A longitudinal real-world study in patients with Alzheimer's Disease dementia using frequent multi-domain digital measurements performed at-home on the Cumulus Neuroassessment Platform: usability and feasibility findings
- Session: Technology and Dementia Preconference Posters
- Date & Time: Saturday, July 27, 2024, 8:00 AM – 3:00 PM EDT
- Poster Number: 94325

3. Technology and Dementia Data Blitz
- Title: Machine-learning analysis of real-world multimodal data collected autonomously at home detects dementia as precisely as a traditional composite scale
- Session: Technology and Dementia Data Blitz
- Date & Time: Saturday, July 27, 2024, 11:40 AM – 12:20 PM EDT
- Poster Number: 94323

4. Alzheimer's Association International Conference (AAIC)
- Title: Machine-learning analysis of real-world multimodal data collected autonomously at home detects dementia as precisely as a traditional composite scale
- Session: Biomarkers: Biomarkers (non-neuroimaging)
- Date & Time: Tuesday, July 30, 2024, 8:00 AM – 4:15 PM EDT
- Poster Number: 92145

5. Alzheimer's Association International Conference (AAIC)
- Title: A longitudinal real-world study in patients with Alzheimer's Disease dementia using frequent multi-domain digital measurements performed at-home on the Cumulus Neuroassessment Platform: usability and feasibility findings
- Session: Biomarkers: Biomarkers (non-neuroimaging)
- Date & Time: Tuesday, July 30, 2024, 8:00 AM – 4:15 PM EDT
- Poster Number: 92164

Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus, emphasized the limitations of traditional Alzheimer's clinical measures, which often lack objectivity and scalability. These conventional methods require patients to attend clinic appointments, an often stressful process that can affect results. Murphy highlighted the need for scalable digital biomarkers that provide objective, longitudinal measures of brain function in real-world settings. He expressed gratitude to study participants and collaborators, acknowledging their dedication to understanding Alzheimer’s and advancing therapy development.

Alzheimer's disease is a progressive disorder affecting brain function, memory, and other cognitive abilities, leading to symptoms like memory loss, confusion, and behavioral changes. It remains the most prevalent cause of dementia, impacting millions globally, with no known cure to date.

Cumulus Neuroscience supports precision in CNS clinical trials through its capability for remote patient monitoring across multiple brain function domains. The company’s mission is to generate data and insights to accelerate the diagnosis and management of CNS disorders, benefiting millions of patients and caregivers worldwide. Cumulus advances its mission with its NeuLogiq™, an AI-based digital biomarker platform designed to facilitate better decision-making in neurology and neuropsychiatry clinical trials and patient care.

The platform, developed with input from ten leading pharmaceutical companies, enables decentralized trials and significantly influences the development of therapies for conditions such as Alzheimer’s disease, depression, and schizophrenia. Cumulus combines patented technology, expert in-house knowledge, and key industry partnerships to capture extensive real-world clinical data.

The company is supported by specialized investors, including DDF/SV Health Investors, LifeArc, and Future Fund, alongside a distinguished Scientific and Technical Advisory Board.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!